Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Health Canada grants Response Biomedical Class 3 Medical Device license for RAMP RSV Assay

Response Biomedical Corporation today announced that it has been granted a Class 3 (near patient/point-of-care) Medical Device license by Health Canada to market its RAMP® Respiratory Syncytial Virus (RSV) Assay in Canada.

18 May 2010

Apnex HGNS System shows promising results in people suffering from OSA

Apnex Medical announced today that preliminary data from a first-in-man clinical study showed significant improvements in sleep for people suffering from obstructive sleep apnea. The Apnex HGNS™ System, developed by the St. Paul-based company, is a device designed to treat OSA, which is a serious life-threatening illness characterized by fragmented sleep and excessive day-time sleepiness.

18 May 2010

Cardiocom releases new pulse oximeter

Cardiocom today announced the release of its new pulse oximeter. Cardiocom's internally developed pulse oximeter offers better integration with its telehealth platform. Cardiocom designs and manufactures telehealth communication devices and vital sign peripherals including: blood pressure system, weight scale, and now offers its new pulse oximeter.

17 May 2010

Aastrom Biosciences initiates treatment in Phase 2 catheter-based clinical trial for dilated cardiomyopathy

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that the first patient has been treated in the company's U.S. Phase 2 catheter-based clinical trial to treat dilated cardiomyopathy (DCM). Treatment was performed by interventional cardiologist Timothy D. Henry, M.D., FACC, at the Minneapolis Heart Institute® at Abbott Northwestern Hospital in Minneapolis, MN.

17 May 2010

ARCA biopharma announces SPA agreement with FDA for bucindolol clinical trial

ARCA biopharma, Inc. today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a clinical trial to assess the safety and efficacy of bucindolol in approximately 3,200 patients with chronic heart failure who have the genotype that appears to respond most favorably to bucindolol. Bucindolol is the Company's investigational, pharmacologically unique, beta-blocker and mild vasodilator.

17 May 2010

New data from MVP trial on ICDs shows health care use burden

Medtronic, Inc. today released new data from the MVP trial that implantable defibrillator patients receiving anti-tachycardia pacing were less likely to have health care utilization after treatment as compared to those receiving shock therapy.

17 May 2010

Long-term, regular use of vitamin E in women may help decrease risk of COPD: Study

Long-term, regular use of vitamin E in women 45 years of age and older may help decrease the risk of chronic obstructive pulmonary disease by about 10 percent in both smokers and non-smokers, according to a study conducted by researchers at Cornell University and Brigham and Women's Hospital.

17 May 2010

STOP AF trial: Arctic Front Cardiac CryoAblation Catheter System reduces AF symptoms by 80%

Medtronic, Inc. today released new STOP AF clinical trial data showing the number of paroxysmal atrial fibrillation patients reporting AF symptoms declined by 80 percent after treatment with the Arctic Front Cardiac CryoAblation Catheter System.

15 May 2010

Nile Therapeutics reports net loss of $1.9M for first-quarter 2010

Nile Therapeutics, Inc., a company focused on the development of novel therapeutics for heart failure patients, today announced its first quarter financial results for 2010.

14 May 2010

FREEDOM trial results to be presented at Heart Rhythm 2010

St. Jude Medical, Inc., a global medical device company, today announced results of the FREEDOM trial during the late breaking clinical trial presentations at Heart Rhythm 2010, the Heart Rhythm Society's 31st Annual Scientific Sessions. The trial demonstrated that the QuickOpt optimization feature available in St. Jude Medical cardiac resynchronization therapy devices produces an equivalent response rate in CRT patients as optimization using echocardiography.

14 May 2010

GRNCM1 do not cause cardiac arrhythmias after transplantation: Preclinical study

Geron Corporation today reported positive preclinical study data showing that GRNCM1, Geron's cardiomyocyte product derived from human embryonic stem cells, does not cause cardiac arrhythmias after transplantation into a model of chronic heart damage designed to test this potential safety concern.

14 May 2010

GE Healthymagination Fund invests $5M in CardioDx

GE Healthcare, the healthcare business of GE and CardioDx, a pioneer in cardiovascular genomic diagnostics, announced today that the companies have entered into a strategic alliance to advance and co-develop diagnostic technologies to improve the care and management of patients with cardiovascular disease.

14 May 2010

Boston Scientific's ACUITY Break-Away Lead Delivery System receives FDA clearance

Boston Scientific Corporation today announced U.S. Food and Drug Administration clearance of the ACUITY Break-Away Lead Delivery System for use with cardiac resynchronization therapy defibrillators and cardiac resynchronization therapy pacemakers, both of which treat heart failure.

14 May 2010

ARCA biopharma regains compliance for continued listing on NASDAQ

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular disease, today announced that it received notification from the NASDAQ Stock Market that the Company has demonstrated compliance with the minimum stockholders' equity requirement for the NASDAQ Global Market

13 May 2010

St. Jude Medical to display new products, clinical solutions at Heart Rhythm 2010

St. Jude Medical, Inc., a global medical device company, today announced it will display a number of new products and clinical solutions from the company's Cardiac Rhythm Management and Atrial Fibrillation Divisions at Heart Rhythm 2010, the Heart Rhythm Society's 31st Annual Scientific Sessions.

13 May 2010

FDA approves St. Jude Medical's Unify CRT-D and Fortify ICD devices

St. Jude Medical, Inc., a global medical device company, today announced U.S. Food and Drug Administration (FDA) approval and first U.S. implants of its Unify™ cardiac resynchronization therapy defibrillator (CRT-D) and Fortify™ implantable cardioverter defibrillator (ICD). The new devices feature advanced battery technology and circuitry that allow for the smallest device footprint in the industry and rapid charge times, without any compromise in device longevity or power.

13 May 2010

Pfizer to acquire terguride from Ergonex Pharma GmbH for treatment of PAH

Pfizer Inc. and Ergonex Pharma GmbH announced today that they have entered into an agreement under which Pfizer will acquire terguride, which is in development as a potential treatment for Pulmonary Arterial Hypertension.

13 May 2010

Clinical Data expands PGxHealth's FAMILION tests to include two new tests to diagnose heart diseases

Clinical Data, Inc., announced today that its PGxHealth division is expanding its FAMILION family of genetic tests to include two new tests to diagnose heart diseases. With the launch of a test for Conduction Disease associated with Dilated Cardiomyopathy and a test for Short QT Syndrome, PGxHealth continues to lead the industry with the most comprehensive menu of genetic tests to diagnose or confirm familial heart diseases.

12 May 2010

St. Jude Medical launches Promote Quadra CRT-D in Europe

St. Jude Medical, Inc., a global medical device company, today announced the European launch of its Promote Quadra™ cardiac resynchronization therapy defibrillator (CRT-D). The Promote Quadra CRT-D is the industry's first quadripolar pacing system, which offers physicians the ability to more effectively and efficiently manage the ever-changing pacing needs of patients with heart failure.

12 May 2010

CHD mortality rate in Ontario decreased by 35%: Study

From 1994 to 2005 in Ontario, Canada, there was a 35 percent decrease in the rate of deaths from coronary heart disease, with about half of this reduction associated with improvements in traditional CHD risk factors such as total cholesterol levels and systolic blood pressure, according to a study in the May 12 issue of JAMA.

12 May 2010

Heart Failure News and Research

Further Reading

Health Canada grants Response Biomedical Class 3 Medical Device license for RAMP RSV Assay

Apnex HGNS System shows promising results in people suffering from OSA

Cardiocom releases new pulse oximeter

Aastrom Biosciences initiates treatment in Phase 2 catheter-based clinical trial for dilated cardiomyopathy

ARCA biopharma announces SPA agreement with FDA for bucindolol clinical trial

New data from MVP trial on ICDs shows health care use burden

Long-term, regular use of vitamin E in women may help decrease risk of COPD: Study

STOP AF trial: Arctic Front Cardiac CryoAblation Catheter System reduces AF symptoms by 80%

Nile Therapeutics reports net loss of $1.9M for first-quarter 2010

FREEDOM trial results to be presented at Heart Rhythm 2010

GRNCM1 do not cause cardiac arrhythmias after transplantation: Preclinical study

GE Healthymagination Fund invests $5M in CardioDx

Boston Scientific's ACUITY Break-Away Lead Delivery System receives FDA clearance

ARCA biopharma regains compliance for continued listing on NASDAQ

St. Jude Medical to display new products, clinical solutions at Heart Rhythm 2010

FDA approves St. Jude Medical's Unify CRT-D and Fortify ICD devices

Pfizer to acquire terguride from Ergonex Pharma GmbH for treatment of PAH

Clinical Data expands PGxHealth's FAMILION tests to include two new tests to diagnose heart diseases

St. Jude Medical launches Promote Quadra CRT-D in Europe

CHD mortality rate in Ontario decreased by 35%: Study

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News